Share Name Share Symbol Market Type Share ISIN Share Description
Vindon Healthcare LSE:VDN London Ordinary Share GB00B06N4S86 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 13.25p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 7.2 0.9 0.9 14.7 11.77

Vindon Healthcare Share Discussion Threads

Showing 351 to 375 of 375 messages
Chat Pages: 15  14  13  12  11  10  9  8  7  6  5  4  Older
DateSubjectAuthorDiscuss
30/7/2015
15:40
SBS now nudging 16p and another acquisition target announced
buywell3
31/10/2013
22:22
SBS now trading at 10.75p Sellers of VDN stock that ploughed their cash into SBS shares would have done OK it seems
buywell2
11/10/2013
21:07
So no interims from Vindon and no dividend Presumably the profit and dividend payment that were to happen now get ploughed into SBS , now trading at 10p
buywell2
18/9/2013
16:18
The 'squeeze' .... OFFER CLOSING FOR FURTHER ACCEPTANCES AND COMPULSORY ACQUISITION OF VINDON SHARES On 17 September 2013, Source BioScience announced that its recommended cash offer to acquire the entire issued and to be issued share capital of Vindon had been declared unconditional in all respects. Source BioScience today announces that the Offer will be closed to further acceptances with effect from 2 October 2013. Source BioScience has today implemented the procedure under Chapter 3 of Part 28 of the Companies Act 2006 to compulsorily acquire all of the outstanding Vindon Shares which it does not already hold or has not already acquired, contracted to acquire or in respect of which it has not already received valid acceptances. Letters have been sent to non-assenting Vindon Shareholders informing them of the intended exercise by Source BioScience of its right under section 979 of the Companies Act 2006 (the "Act") to 'squeeze-out' such Vindon Shareholders, together with a notice of such action pursuant to section 980(1) of the Act. Settlement of the consideration to which any Vindon Shareholders (or, in the absence of any contrary direction as specified in the Offer Document, the first named shareholder in the case of joint shareholders) are entitled under the Offer will be effected (in the manner set out in paragraph 20 of Part II of the Offer Document): (i) in the case of acceptances received on or before 13 September 2013, complete in all respects, by 27 September 2013 or, (ii) in the case of acceptances received, complete in all respects, after 13 September 2013 but on or before 2 October 2013, within 14 days of such receipt. Non-assenting shareholders who do not accept the Offer by 2 October 2013 will not receive payment until after compulsory purchase has been implemented on 30 October 2013. ...
piedro
13/9/2013
12:19
............................................................................................. Vindon Flexible approach to cabinet manufacture We often tailor our manufacturing expertise according to clients' demands and market requirements: We have provided a temperature-only photostability cabinet to operate from 4-40ºC. We simply adapted a standard 5799 cabinet and four reach-in chambers, capable of being moved without being stripped down. We also manufactured a temperature and humidity cycling cabinet to operate at -30 to +60ºC, we modified a 5804-SM cabinet to include increased insulation and direct refrigeration, as well as adding a slide actuator and programmable controller. ............................................................................................. Temperature and humidity cycling service Vindon has a new service available now in the UK and available soon at our USA and Ireland facilities. This comprises a wide range of state-of-the art environmental test facilities to simulate temperature and humidity conditions, replicating natural and man-made climatic environments. In order to assess the ability of client samples to withstand exposure to several environmental conditions, we have recently added temperature and humidity cycling testing. source; Linkedin .............................................................................................
piedro
02/9/2013
10:47
Mr Yeung Yu Loong has now increased his SBS holding to 5.55% Any VDN holders or ex-holders have any comments on Source BioSciences.
piedro
29/8/2013
10:24
When VDN delist from AIM are you planning to run a SBS thread Piedro I have no problem with you doing so I draw your attention to the follwowing ''Source BioScience further announces that the Offer, which remains subject to the terms and conditions set out or referred to in the Offer Document is being extended for 14 days and will remain open for acceptance until the next closing date which will be 1.00 pm on 11 September 2013. Any further extensions of the Offer Period will be publicly announced no later than 8.00 a.m. on the Business Day following the date on which the Offer was otherwise due to expire, or such later date or time as the Panel may agree. The Offer Price remains unchanged in connection with this extension. Intention to delist Vindon Shares from trading on AIM Assuming that the Offer becomes or is declared unconditional in all respects and subject to any applicable requirements by the AIM Rules, Source BioScience intends to procure that Vindon applies to the London Stock Exchange for the cancellation of the admission of the Vindon Shares to trading on AIM. It is anticipated that such cancellation of listing and trading will take effect no earlier than 20 Business Days after the Offer becomes or is declared unconditional in all respects, subject to compliance with applicable requirements of the AIM Rules. Vindon Shareholders are strongly recommended to accept the Offer as the delisting will significantly reduce the liquidity and marketability of any Vindon Shares in respect of which acceptances of the Offer are not submitted.'' Source BioScience PLC Offer Update Share On Facebook Print Alert TIDMSBS TIDMVDN RNS Number : 7218M Source BioScience PLC 29 August 2013 Source BioScience PLC ("Source BioScience") RECOMMENDED CASH OFFER FOR VINDON HEALTHCARE PLC ("VINDON") First Closing Date Announcement Background On 7 August 2013 the Boards of Directors of Source BioScience and Vindon announced the terms of a recommended cash offer to be made by Source BioScience for the entire issued ordinary share capital of Vindon at 13.7p per Vindon Share (the "Offer"). The full terms of, and conditions to, the Offer together with the procedure for acceptance were set out in the offer document issued by Source BioScience on 7 August 2013 (the "Offer Document") and in respect of Vindon Shares held in certificated form, in the form of acceptance. Level of acceptances As required by the City Code, Source BioScience announces that as at 1.00 pm on 28 August 2013 (being the first closing date of the Offer), Source BioScience had received valid acceptances in respect of 73,521,849 Vindon Shares, representing approximately 82.75 per cent. of the entire issued share capital of Vindon. As at the date of this announcement, Source BioScience holds 150,000 shares, representing 0.2 per cent. of the entire issued share capital of Vindon. These acceptances include acceptances received in respect of the following, from: (i) 15,500,000 Vindon Shares, representing approximately 17.44 per cent. of Vindon's entire issued share capital which were subject to irrevocable commitments procured by Source BioScience from the Vindon Directors; (ii) 7,150,000 Vindon Shares, representing approximately 8.05 per cent. of Vindon's entire issued share capital which were subject to irrevocable commitments procured by Source BioScience from the Independent Vindon Directors; and (iii) 25,722,984 Vindon Shares, representing approximately 28.95 per cent. of Vindon's entire issued share capital which were subject to irrevocable commitments procured by Source BioScience from certain other Vindon Shareholders. Accordingly as at 1.00 p.m. on 28 August 2013, Source BioScience either owned or had received valid acceptances of the Offer in respect of a total of 73,671,849 shares, representing, in aggregate, approximately 82.9 per cent. of the entire issued share capital of Vindon. Source BioScience has also received irrevocable undertakings to accept the Offer from Gary Middlebrook in respect a further 1,640,000 shares for which valid acceptances have yet to be received. These undertakings may be withdrawn if the Offer is withdrawn or lapses. Save as disclosed above, neither Source BioScience nor its associates have any other outstanding irrevocable commitments to accept the Offer. Extension of the Offer Source BioScience further announces that the Offer, which remains subject to the terms and conditions set out or referred to in the Offer Document is being extended for 14 days and will remain open for acceptance until the next closing date which will be 1.00 pm on 11 September 2013. Any further extensions of the Offer Period will be publicly announced no later than 8.00 a.m. on the Business Day following the date on which the Offer was otherwise due to expire, or such later date or time as the Panel may agree. The Offer Price remains unchanged in connection with this extension. Intention to delist Vindon Shares from trading on AIM Assuming that the Offer becomes or is declared unconditional in all respects and subject to any applicable requirements by the AIM Rules, Source BioScience intends to procure that Vindon applies to the London Stock Exchange for the cancellation of the admission of the Vindon Shares to trading on AIM. It is anticipated that such cancellation of listing and trading will take effect no earlier than 20 Business Days after the Offer becomes or is declared unconditional in all respects, subject to compliance with applicable requirements of the AIM Rules. Vindon Shareholders are strongly recommended to accept the Offer as the delisting will significantly reduce the liquidity and marketability of any Vindon Shares in respect of which acceptances of the Offer are not submitted. Acceptance procedure To accept the Offer in respect of shares held in certificated form, the completed and signed Form of Acceptance should be returned and received, in accordance with the instructions printed thereon, by the Receiving Agent as soon as possible and, in any event, by no later than 1.00 p.m. on 11 September 2013. To accept the Offer in respect of shares held in uncertificated form (that is, in CREST), electronic acceptances should be made and settled, in accordance with the instructions set out in the Offer Document, as soon as possible and, in any event, by no later than 1.00 p.m. on 11 September 2013. Shareholders who have not accepted the Offer are urged to do so as soon as possible and in any event by 1.00 p.m. on 11 September 2013. Interests in relevant securities Save for the interests set out in this announcement, as at the date of this announcement, neither Source BioScience, nor any of the Source BioScience Directors or any other member of the Source BioScience Group, nor so far as the Source BioScience Directors are aware, any person acting in concert (within the meaning of the City Code) with Source BioScience for the purposes of the Offer, has any interest in, right to subscribe for, or has borrowed or lent any shares or securities convertible or exchangeable into shares (including pursuant to any long exposure, whether conditional or absolute, to changes in the prices of securities) or rights to subscribe for or purchase the same or holds any options (including traded options) in respect of or has any right to acquire any shares or derivatives referenced to shares ("Vindon Securities"), nor does any such person have any short position (whether conditional or absolute and whether in the money or otherwise) including any short position under a derivative, any agreement to sell or any delivery obligation or right to require another person to purchase or take delivery in relation to Vindon Securities. General Terms used in this announcement have the same meaning as in the Offer Document, unless stated otherwise. This announcement does not constitute or form part of any offer or invitation to sell or purchase any securities or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, pursuant to the Offer or otherwise. The Offer is made solely by the Offer Document which contains the full terms and conditions of the Offer, including details of how the Offer may be accepted. Please carefully read the Offer Document in its entirety before making a decision with respect to the Offer.
buywell2
29/8/2013
07:46
'' Source BioScience said its 13.7p a share offer for Vindon Healthcare had received valid acceptances totalling 82.9% of that company's issued share capital. It extended its offer to Sept. 11 '' Source Bioscience H1 pretax profit rises to £0.6m 29 August 2013 | 08:14am Source Bioscience's first-half pretax profit rises to £0.6 million, from £0.4 million. Revenue rose to £8.8 million, from £8.4 million. "The encouraging first half of the year represents a continuation of the strong growth and business performance achieved last year and reflects the substantial opportunities we see for further development across both our Healthcare and LifeSciences divisions," said chairman Laurie Turnbull in a statement. Separately, Source BioScience said its 13.7p a share offer for Vindon Healthcare had received valid acceptances totalling 82.9% of that company's issued share capital. It extended its offer to Sept. 11. www.stockmarketwire.com/article/4658448/Source-Bioscience-H1-pretax-profit-rises-to-0-point-6m.html#sthash.jKPc4K5f.dpuf
buywell2
29/8/2013
06:45
Vindon is going to belong to Source BioScience Piedro That you have most likely lost money on your investment is not my fault and is no excuse for being rude What you have to decide is whether you want to become a SBS shareholder, if you believe enough in the Vindon story that you have written here on advfn thus far that you still want to carry on with it albeit under another name but still with the VDN CEO on the board Check out SBS results today
buywell2
25/8/2013
12:24
buywell2, I don't think you are doing any favours to SBS coming on this thread and spouting sensationalism. Please moderate your tone and present the facts as facts with their rightful reference links and your opinion as your opinion which may be distinguished by IMO or IMHO etc to avoid confusion.
piedro
24/8/2013
07:28
All SBS AGM resolutions passed ... it's a done deal Source BioScience will start offering ''Over Night''/''Same Day'' DNA Sequencing Services from BOTH Vindon California (West Coast Life Sciences Pharma Biotech hub and Vindon Atlanta ( East Coast Life Sciences Pharma Biotech hub) most likely by the end of September. For starters Read yesterdays new about NHS UK to open Hospitals in India ..... lots of new opportunities
buywell2
22/8/2013
06:29
Have you sold your VDN shares Piedro yet ?
buywell2
20/8/2013
07:51
Won't happen If you read the SBS prospectus re the takeover BIG Institutions that have backed the offer include Hendeson Global have UPPED their stake to circa 12.5% from current 5.5% plus Artemis have just arrived taking a maiden circa 8.5% Legal and General add to stay at 8% plus at least 3 more who have added to stay at around 6% Even SBS management/staff and Directors add to stay at just over 6% This is a done deal Institutions like those will look after their investment, the only thing that might upset the applecart is voting on resolutions 1, 2, 3, 4 by SBS shareholders While you are at it Take a butchers at my Cyprotex thread (CRX) BIG Institutional buying there also recently
buywell2
19/8/2013
11:20
Re: Ian Yeung Thank you for the confirmation Those 8.5m shares give more weight to his arguments Certainly the share price has taken a tumble since the offer. 8p/share would be interesting.
piedro
19/8/2013
10:56
buywell2 Re: "I take it you read my posts ... " I confess to having some difficulty reading your SBS posts; - finding a confusion in distinguishing between "quotations", ''quotations'' and your personal opinions. - headers and following text disconnected. - line spacing can be erratic. - the links are not activate-able. eg: www.uk.advfn.com/cmn/fbb/thread.php3?id=16690316 vs: http://uk.advfn.com/cmn/fbb/thread.php3?id=16690316 Thus, I do not give the attention to them that they possibly deserve. No offense intended, it's just the way I work. P.
piedro
19/8/2013
07:11
My logic ran thus .... If you were a fan of Vindon , then I thought you would be a fan of the company that bought them with a view of increasing both Vindons sales and Source BioSciences sales by X selling to each others clients. Re that article again you posted That Ian Yeung is in fact the same Ian Yu Loong Yeung , a Physician educated in Cambridge 2001 and 2002 coming out with a MB , ex Hong Kong , who recently took a 4% plus stake in SBS about a month back. I take it you read my posts on the positive growth projections for the 'cold storage' business re Pharmas/Hospitals/research facilities/drug storage etc that I did on the SBS thread.
buywell2
16/8/2013
12:34
I admit to not having done much research on SBS Why do you think that I "need to do more"? I have no interest in the company except as a passing curiosity. [edited]
piedro
16/8/2013
09:47
Then you need to do more research Piedro ... read their interims next week to see how struggling they are Do you feel you have been sold down the river by your BoD ?
buywell2
15/8/2013
10:49
Thank you, Mr. Yeung was of the opposition note then. He does make some interesting points which are well worth being considered by SBS shareholders - IMHO In the offer document (downloadable from the VDN website) it is stated that SBS intends to continue with Vindon's current activities and that their places of business and fixed assets will remain unchanged. Also most of Vindon's directors and senior management will remain in the enlarged group As Mr. Yeung points out, this will change the nature of SBS and suggest to me that perhaps they also are struggling to find their niche
piedro
15/8/2013
09:58
Piedro from the link YOU posted but obviously never read in post 254 And posted on the SBS thread. You do know I trust running this Vindon thread that they OUTSOURCE the manufacture of cold cabinets/Rooms do you not ? I don't think you will get to see Interims ..... acquisition event will probably kick in prior to that. I do hope the Vindon BoD sink their dough into SBS stock .... would show faith in their Vindon Products Here is what Ian Yeung said from YOUR unread link Member Ian Yeung has said: SBS is in the business of cell biology,histopathology and genetic sequencing. Vindon does many things, and if you see the statement from SBS, there are some synergies. But if you look, a fair amount of Vindon's money comes from the manufacture of steel cabinets and rooms for laboratories. The points I would like to raise are: 1. Personally I feel that this kind of thing sounds more like an engineering/ manufacturing type business. And I don't think it's entirely matches up to what SBS does as a cell biology/genetic sequencing company.
buywell2
15/8/2013
09:46
Interim Results should be out this month
piedro
15/8/2013
09:34
Please excuse my ignorance ... Who is Ian Yeung?
piedro
15/8/2013
06:29
Course they do .... they love it That Ian Yeung guy is a bit out of kilter with what Vindon do They OUTSOURCE the contstruction of cold cabinets/rooms and then use in house staff to add value to the carcass back at the ranch piedro Do you think any of the BoD will be buyers of SBS shares using their new wedge ?
buywell2
13/8/2013
10:45
Spot the Clown. Do the Americans like this sort of Circus?
piedro
12/8/2013
15:00
Article in the ShareSoc Informer re: Source BioScience offer for VDN hxxp://www.sharesoc.com/S8PR1835.pdf ... you may need to register to read the article (free) ... not everyone is in agreement
piedro
Chat Pages: 15  14  13  12  11  10  9  8  7  6  5  4  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20161204 14:12:14